It is noteworthy that the prognosis of patients with ER+ breast cancer with high UBE2M expression was poorer than that of patients with low UBE2M expression (OS, p = 2.3e-5; HR = 1.67; RFS, p = 0.0048, HR = 1.19) (Fig. 1D, E). Here, ESR1 is linked to breast cancer.